Esperion Therapeutics Inc’s recently made public that its Chief Financial Officer Halladay Benjamin unloaded Company’s shares for reported $7866.0 on Dec 17 ’24. In the deal valued at $2.42 per share,3,245 shares were sold. As a result of this transaction, Halladay Benjamin now holds 240,691 shares worth roughly $0.56 million.
Then, Warren Eric sold 2,234 shares, generating $5,426 in total proceeds. Upon selling the shares at $2.43, the Chief Commercial Officer now owns 160,121 shares.
Before that, Koenig Sheldon L. sold 12,447 shares. Esperion Therapeutics Inc shares valued at $30,694 were divested by the President and CEO at a price of $2.47 per share. As a result of the transaction, Koenig Sheldon L. now holds 739,819 shares, worth roughly $1.73 million.
Goldman initiated its Esperion Therapeutics Inc [ESPR] rating to a Neutral in a research note published on December 18, 2024; the price target was $4. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid December with a ‘”an Overweight”‘ rating. BofA Securities also remained covering ESPR and has decreased its forecast on June 20, 2024 with a “an Underperform” recommendation from previously “Neutral” rating. BofA Securities revised its rating on January 03, 2024. It rated ESPR as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ESPR
On Friday, Esperion Therapeutics Inc [NASDAQ:ESPR] saw its stock jump 7.83% to $2.34. Over the last five days, the stock has gained 6.36%. Esperion Therapeutics Inc shares have risen nearly 6.36% since the year began. Nevertheless, the stocks have fallen -16.13% over the past one year. While a 52-week high of $3.94 was reached on 01/10/25, a 52-week low of $1.58 was recorded on 01/03/25. SMA at 50 days reached $2.44, while 200 days put it at $2.24.
Levels Of Support And Resistance For ESPR Stock
The 24-hour chart illustrates a support level at 2.19, which if violated will result in even more drops to 2.04. On the upside, there is a resistance level at 2.42. A further resistance level may holdings at 2.50. The Relative Strength Index (RSI) on the 14-day chart is 49.22, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 7.70%. Stochastics %K at 45.34% indicates the stock is a holding.
How much short interest is there in Esperion Therapeutics Inc?
A steep rise in short interest was recorded in Esperion Therapeutics Inc stocks on 2024-12-13, dropping by -5.77 million shares to a total of 25.47 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 31.25 million shares. There was a decline of -22.66%, which implies that there is a negative sentiment for the stock.
